Genfit S.A. Market Cap ($244.43 Million)
Market Cap & Net Worth: Genfit S.A. (GNFT)
Genfit S.A. market cap. Genfit S.A. (NASDAQ:GNFT) has a market capitalization of $244.43 Million ($244.43 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15516 globally and #3693 in its home market, demonstrating a -3.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genfit S.A.'s stock price $5.97 by its total outstanding shares 50002896 (50.00 Million). Also see Genfit S.A. cash flow conversion for how efficiently the company converts equity into cash flow.
Genfit S.A. Market Cap History (2019–2026)
Genfit S.A. market cap history from 2019 to 2026. Data shows change from $995.06 Million to $298.52 Million (-17.48% CAGR). Check Genfit S.A. (GNFT) share price today for real-time trading data and today's change.
Index Memberships
Genfit S.A. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #410 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1512 of 3165 |
Weight: Genfit S.A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genfit S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genfit S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Genfit S.A. (GNFT) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.77x
Genfit S.A.'s market cap is 2.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
123.27x
Genfit S.A.'s market cap is 123.27 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $995.06 Million | $30.84 Million | -$65.14 Million | 32.27x | N/A |
| 2020 | $240.01 Million | $765.00K | -$101.22 Million | 313.74x | N/A |
| 2021 | $250.01 Million | $80.07 Million | $67.26 Million | 3.12x | 3.72x |
| 2022 | $219.46 Million | $20.20 Million | -$23.72 Million | 10.87x | N/A |
| 2023 | $192.51 Million | $28.57 Million | -$28.89 Million | 6.74x | N/A |
| 2024 | $185.76 Million | $67.00 Million | $1.51 Million | 2.77x | 123.27x |
Competitor Companies of GNFT by Market Capitalization
Companies near Genfit S.A. in the global market cap rankings as of November 4, 2026. Also see GNFT current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Genfit S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Genfit S.A. (2019–2026)
Market capitalization of Genfit S.A. from 2019 to today. Between 2019 and today, Genfit S.A.'s market cap moved from $995.06 Million to $ 298.52 Million, with a yearly change of -17.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $298.52 Million | -2.93% |
| 2025 | $307.52 Million | +65.55% |
| 2024 | $185.76 Million | -3.51% |
| 2023 | $192.51 Million | -12.28% |
| 2022 | $219.46 Million | -12.22% |
| 2021 | $250.01 Million | +4.17% |
| 2020 | $240.01 Million | -75.88% |
| 2019 | $995.06 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Genfit S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $244.43 Million USD |
| MoneyControl | $244.43 Million USD |
| MarketWatch | $244.43 Million USD |
| marketcap.company | $244.43 Million USD |
| Reuters | $244.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genfit S.A.
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more